AKESO (09926) released its interim results, with revenue increasing by 27.92% year-on-year to 1.806 billion yuan.

AKESO (09926) announced its interim results for the six months ending June 30, 2026, reporting revenues of 1.806 billion yuan (RMB, hereinafter the same), an increase of 27.92% year-on-year; a gross profit of 1.34 billion yuan, an increase of 19.62% year-on-year; and R&D expenses of 783 million yuan, an increase of 7.12% year-on-year. The loss attributable to shareholders of the parent company was 424 million yuan, with a loss per share of 0.46 yuan. The announcement indicated that the company's commercial sales revenue was approximately 1.803 billion yuan, a year-on-year increase of 28.65% compared to 1.402 billion yuan during the same period last year, primarily benefiting from significant sales contributions from the two tumor immunotherapy dual antibodies, Katanib (Cadonil, PD1/CTLA4) and Yidafang (Ywosi, PD1/VEGF). Other commercially available products from the company also contributed to sales growth, including Yixinning (Inusi, PCSK9) and Aida Luo (Yiruoqi, IL12/IL23). The first five self-developed commercial innovative drugs, with a total of 12 approved indications, have been included in the latest national medical insurance catalog, and the hospital access has also achieved wide coverage and deep penetration. As of June 30, 2026, the company has established a specialized and systematic sales team of over 1,600 personnel, covering the two core areas of oncology and specialty drugs. The company actively practices academic marketing with a patient-centered approach, widely exploring diverse channels such as commercial insurance, driving sustainable growth of the existing product portfolio and maximizing synergy advantages. In addition, during the reporting period, the company also received commercial licensing income of 2.5 million yuan from partners for two products.